Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Autoimmune Disorders

  Free Subscription


Articles published in Mult Scler

Retrieve available abstracts of 370 articles:
HTML format
Text format



Single Articles


    December 2018
  1. POURCHER V, Todesco E, Dubois C, Pallier C, et al
    False hepatitis B and C viral serologies in patients with multiple sclerosis receiving high-dose biotin.
    Mult Scler. 2018 Dec 11:1352458518818294. doi: 10.1177/1352458518818294.
    PubMed     Text format    


  2. BSTEH G, Algrang L, Hegen H, Auer M, et al
    Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.
    Mult Scler. 2018 Dec 3:1352458518816614. doi: 10.1177/1352458518816614.
    PubMed     Text format     Abstract available


  3. VAUGHN CB, Kavak KS, Dwyer MG, Bushra A, et al
    Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium.
    Mult Scler. 2018 Dec 3:1352458518816619. doi: 10.1177/1352458518816619.
    PubMed     Text format     Abstract available


    November 2018
  4. CHIEN C, Scheel M, Schmitz-Hubsch T, Borisow N, et al
    Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity.
    Mult Scler. 2018 Nov 26:1352458518815596. doi: 10.1177/1352458518815596.
    PubMed     Text format     Abstract available


  5. BSTEH G, Berek K, Hegen H, Teuchner B, et al
    Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration.
    Mult Scler. 2018 Nov 22:1352458518814113. doi: 10.1177/1352458518814113.
    PubMed     Text format     Abstract available


  6. WOJCIK CM, Rao SM, Schembri AJ, Drake AS, et al
    Necessity of technicians for computerized neuropsychological assessment devices in multiple sclerosis.
    Mult Scler. 2018 Nov 22:1352458518813287. doi: 10.1177/1352458518813287.
    PubMed     Text format     Abstract available


  7. WALLECZEK NK, Frommlet F, Bsteh G, Eggers C, et al
    Month-of-birth-effect in multiple sclerosis in Austria.
    Mult Scler. 2018 Nov 22:1352458518810924. doi: 10.1177/1352458518810924.
    PubMed     Text format     Abstract available


  8. SEGAL BM
    Enhancing natural killer cells is beneficial in multiple sclerosis - Commentary.
    Mult Scler. 2018 Nov 13:1352458518809296. doi: 10.1177/1352458518809296.
    PubMed     Text format    


  9. LIU Q, Shi FD
    Enhancing natural killer cells is beneficial in multiple sclerosis - No.
    Mult Scler. 2018 Nov 13:1352458518799591. doi: 10.1177/1352458518799591.
    PubMed     Text format    


  10. LARONI A
    Enhancing natural killer cells is beneficial in multiple sclerosis - Yes.
    Mult Scler. 2018 Nov 13:1352458518800776. doi: 10.1177/1352458518800776.
    PubMed     Text format    


  11. RAATS J, Lamers I, Baert I, Willekens B, et al
    Cognitive-motor interference in persons with multiple sclerosis during five upper limb motor tasks with different complexity.
    Mult Scler. 2018 Nov 12:1352458518808194. doi: 10.1177/1352458518808194.
    PubMed     Text format     Abstract available


  12. FOX EJ, Markowitz C, Applebee A, Montalban X, et al
    Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
    Mult Scler. 2018 Nov 12:1352458518808189. doi: 10.1177/1352458518808189.
    PubMed     Text format     Abstract available


  13. LUIJTEN MA, Eekhout I, D'Hooghe M, Uitdehaag BM, et al
    Development of the Arm Function in Multiple Sclerosis Questionnaire-Short Form (AMSQ-SF): A static 10-item version.
    Mult Scler. 2018 Nov 9:1352458518808197. doi: 10.1177/1352458518808197.
    PubMed     Text format     Abstract available


  14. LAMERS I, Feys P
    Patient reported outcome measures of upper limb function in multiple sclerosis: A critical overview.
    Mult Scler. 2018 Nov 9:1352458518809294. doi: 10.1177/1352458518809294.
    PubMed     Text format    


  15. HYUN JW, Kim Y, Kim G, Kim SH, et al
    Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
    Mult Scler. 2018 Nov 7:1352458518810261. doi: 10.1177/1352458518810261.
    PubMed     Text format     Abstract available


  16. ACHIRON A, Sarova-Pinhas I, Magalashvili D, Stern Y, et al
    Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapy.
    Mult Scler. 2018 Nov 1:1352458518809903. doi: 10.1177/1352458518809903.
    PubMed     Text format     Abstract available


  17. HOBART J, Bowen A, Pepper G, Crofts H, et al
    International consensus on quality standards for brain health-focused care in multiple sclerosis.
    Mult Scler. 2018 Nov 1:1352458518809326. doi: 10.1177/1352458518809326.
    PubMed     Text format     Abstract available


  18. HEALY BC, Zurawski J, Gonzalez CT, Chitnis T, et al
    Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis.
    Mult Scler. 2018 Nov 1:1352458518810159. doi: 10.1177/1352458518810159.
    PubMed     Text format     Abstract available


  19. PEETERS LM, van Munster CE, Van Wijmeersch B, Bruyndonckx R, et al
    Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done!
    Mult Scler. 2018 Nov 1:1352458518807076. doi: 10.1177/1352458518807076.
    PubMed     Text format     Abstract available


    October 2018
  20. FARRELL R
    Clinical commentary on "De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine".
    Mult Scler. 2018 Oct 30:1352458518810661. doi: 10.1177/1352458518810661.
    PubMed     Text format    


  21. PANICUCCI E, Cohen M, Bourg V, Rocher F, et al
    De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine.
    Mult Scler. 2018 Oct 30:1352458518790379. doi: 10.1177/1352458518790379.
    PubMed     Text format     Abstract available


  22. DOBSON R
    Clinical commentary on 'Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: a note of caution'.
    Mult Scler. 2018 Oct 25:1352458518807053. doi: 10.1177/1352458518807053.
    PubMed     Text format    


  23. FEIGE J, Salmhofer H, Hecker C, Kunz AB, et al
    Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: A note of caution.
    Mult Scler. 2018 Oct 25:1352458518807059. doi: 10.1177/1352458518807059.
    PubMed     Text format     Abstract available


  24. AHMAD H, van der Mei I, Taylor BV, Lucas RM, et al
    Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Oct 23:1352458518806103. doi: 10.1177/1352458518806103.
    PubMed     Text format     Abstract available


  25. SOELBERG SORENSEN P, Giovannoni G, Montalban X, Thalheim C, et al
    The Multiple Sclerosis Care Unit.
    Mult Scler. 2018 Oct 23:1352458518807082. doi: 10.1177/1352458518807082.
    PubMed     Text format     Abstract available


  26. ROTSTEIN DL, Cortese M, Fung TT, Chitnis T, et al
    Diet quality and risk of multiple sclerosis in two cohorts of US women.
    Mult Scler. 2018 Oct 23:1352458518807061. doi: 10.1177/1352458518807061.
    PubMed     Text format     Abstract available


  27. STROBER L, DeLuca J, Benedict RH, Jacobs A, et al
    Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.
    Mult Scler. 2018 Oct 18:1352458518808204. doi: 10.1177/1352458518808204.
    PubMed     Text format     Abstract available


  28. BURROWS DJ, McGown A, Jain SA, De Felice M, et al
    Animal models of multiple sclerosis: From rodents to zebrafish.
    Mult Scler. 2018 Oct 15:1352458518805246. doi: 10.1177/1352458518805246.
    PubMed     Text format     Abstract available


  29. DUBUISSON N, Marta M, Gnanapavan S, Turner B, et al
    Inclusion criteria used in trials of people with progressive multiple sclerosis.
    Mult Scler. 2018 Oct 15:1352458518803769. doi: 10.1177/1352458518803769.
    PubMed     Text format    


  30. GRAF J, Ringelstein M, Lepka K, Schaller J, et al
    Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.
    Mult Scler. 2018 Oct 11:1352458518771276. doi: 10.1177/1352458518771276.
    PubMed     Text format     Abstract available


  31. WILLIS MD, Hope-Gill B, Flood-Page P, Joseph F, et al
    Sarcoidosis following alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2018 Oct 11:1352458518790391. doi: 10.1177/1352458518790391.
    PubMed     Text format     Abstract available


  32. PFEUFFER S
    Sarcoidosis following alemtuzumab treatment: Autoimmunity mediated by T cells and interferon-gamma.
    Mult Scler. 2018 Oct 11:1352458518804124. doi: 10.1177/1352458518804124.
    PubMed     Text format    


  33. CONWAY BL, Zeydan B, Uygunoglu U, Novotna M, et al
    Age is a critical determinant in recovery from multiple sclerosis relapses.
    Mult Scler. 2018 Oct 10:1352458518800815. doi: 10.1177/1352458518800815.
    PubMed     Text format     Abstract available


  34. KALB R, Beier M, Benedict RH, Charvet L, et al
    Recommendations for cognitive screening and management in multiple sclerosis care.
    Mult Scler. 2018 Oct 10:1352458518803785. doi: 10.1177/1352458518803785.
    PubMed     Text format     Abstract available


  35. VILARINO-GUELL C, Encarnacion M, Bernales CQ, Sadovnick AD, et al
    Analysis of Canadian multiple sclerosis patients does not support a role for FKBP6 in disease.
    Mult Scler. 2018 Oct 9:1352458518803789. doi: 10.1177/1352458518803789.
    PubMed     Text format    


  36. KREMER D, Akkermann R, Kury P, Dutta R, et al
    Current advancements in promoting remyelination in multiple sclerosis.
    Mult Scler. 2018 Oct 1:1352458518800827. doi: 10.1177/1352458518800827.
    PubMed     Text format     Abstract available


  37. TATEO F, Grassivaro F, Ermani M, Puthenparampil M, et al
    PM2.5 levels strongly associate with multiple sclerosis prevalence in the Province of Padua, Veneto Region, North-East Italy.
    Mult Scler. 2018 Oct 1:1352458518803273. doi: 10.1177/1352458518803273.
    PubMed     Text format     Abstract available


    September 2018
  38. BOSE G, Atkins HL, Bowman M, Freedman MS, et al
    Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis.
    Mult Scler. 2018 Sep 25:1352458518802544. doi: 10.1177/1352458518802544.
    PubMed     Text format     Abstract available


  39. MIN M, Spelman T, Lugaresi A, Boz C, et al
    Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.
    Mult Scler. 2018 Sep 20:1352458518798147. doi: 10.1177/1352458518798147.
    PubMed     Text format     Abstract available


  40. LAVORGNA L, Brigo F, Moccia M, Leocani L, et al
    e-Health and multiple sclerosis: An update.
    Mult Scler. 2018 Sep 19:1352458518799629. doi: 10.1177/1352458518799629.
    PubMed     Text format     Abstract available


  41. ANTONAZZO IC, Poluzzi E, Forcesi E, Riise T, et al
    Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System.
    Mult Scler. 2018 Sep 19:1352458518799598. doi: 10.1177/1352458518799598.
    PubMed     Text format     Abstract available


  42. ROMMER PS, Eichstadt K, Ellenberger D, Flachenecker P, et al
    Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry.
    Mult Scler. 2018 Sep 19:1352458518799580. doi: 10.1177/1352458518799580.
    PubMed     Text format     Abstract available


  43. O'GRADY KP, Dula AN, Lyttle BD, Thompson LM, et al
    Glutamate-sensitive imaging and evaluation of cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Sep 19:1352458518799583. doi: 10.1177/1352458518799583.
    PubMed     Text format     Abstract available


    August 2018
  44. VAN ROSSUM JA, Killestein J, Villar LM, Riskind PN, et al
    gMS-Classifier1 does not predict disability progression in multiple sclerosis.
    Mult Scler. 2018 Aug 31:1352458518798048. doi: 10.1177/1352458518798048.
    PubMed     Text format    


  45. VAN MUNSTER CE, D'Souza M, Steinheimer S, Kamm CP, et al
    Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis.
    Mult Scler. 2018 Aug 31:1352458518796690. doi: 10.1177/1352458518796690.
    PubMed     Text format     Abstract available


  46. O'MAHONY J, Marrie RA, Laporte A, Bar-Or A, et al
    Pediatric-onset multiple sclerosis is associated with reduced parental health-related quality of life and family functioning.
    Mult Scler. 2018 Aug 30:1352458518796676. doi: 10.1177/1352458518796676.
    PubMed     Text format     Abstract available


  47. BOVE R, Bevan C, Crabtree E, Zhao C, et al
    Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis.
    Mult Scler. 2018 Aug 24:1352458518793527. doi: 10.1177/1352458518793527.
    PubMed     Text format     Abstract available


  48. NICHOLAS RS, Han E, Raffel J, Chataway J, et al
    Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials.
    Mult Scler. 2018 Aug 24:1352458518794063. doi: 10.1177/1352458518794063.
    PubMed     Text format     Abstract available


  49. SKJERBAEK AG, Boesen F, Petersen T, Rasmussen PV, et al
    Can we trust self-reported walking distance when determining EDSS scores in patients with multiple sclerosis? The Danish MS hospitals rehabilitation study.
    Mult Scler. 2018 Aug 20:1352458518795416. doi: 10.1177/1352458518795416.
    PubMed     Text format     Abstract available


  50. ANDERSEN C, Sondergaard HB, Bang Oturai D, Laursen JH, et al
    Alcohol consumption in adolescence is associated with a lower risk of multiple sclerosis in a Danish cohort.
    Mult Scler. 2018 Aug 20:1352458518795418. doi: 10.1177/1352458518795418.
    PubMed     Text format     Abstract available


  51. GAUZZI MC
    Vitamin D-binding protein and multiple sclerosis: Evidence, controversies, and needs.
    Mult Scler. 2018 Aug 16:1352458518792433. doi: 10.1177/1352458518792433.
    PubMed     Text format     Abstract available


  52. SELLEBJERG F, Royen L, Soelberg Sorensen P, Oturai AB, et al
    Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Mult Scler. 2018 Aug 16:1352458518794308. doi: 10.1177/1352458518794308.
    PubMed     Text format     Abstract available


  53. VISWANATHAN S, Wah LM
    A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia.
    Mult Scler. 2018 Aug 16:1352458518792430. doi: 10.1177/1352458518792430.
    PubMed     Text format     Abstract available


  54. SEEBACHER B, Kuisma R, Glynn A, Berger T, et al
    Effects and mechanisms of differently cued and non-cued motor imagery in people with multiple sclerosis: A randomised controlled trial.
    Mult Scler. 2018 Aug 14:1352458518795332. doi: 10.1177/1352458518795332.
    PubMed     Text format     Abstract available


  55. PIETROBONI AM, Caprioli M, Carandini T, Scarioni M, et al
    CSF beta-amyloid predicts prognosis in patients with multiple sclerosis.
    Mult Scler. 2018 Aug 7:1352458518791709. doi: 10.1177/1352458518791709.
    PubMed     Text format     Abstract available


  56. ROCCA MA, Meani A, Fumagalli S, Pagani E, et al
    Functional and structural plasticity following action observation training in multiple sclerosis.
    Mult Scler. 2018 Aug 7:1352458518792771. doi: 10.1177/1352458518792771.
    PubMed     Text format     Abstract available


  57. KUSPINAR A, Mayo NE
    Validation of the preference-based multiple sclerosis index.
    Mult Scler. 2018 Aug 2:1352458518792423. doi: 10.1177/1352458518792423.
    PubMed     Text format     Abstract available


  58. TOMASSINI V, Fanelli F, Prosperini L, Cerqua R, et al
    Predicting the profile of increasing disability in multiple sclerosis.
    Mult Scler. 2018 Aug 2:1352458518790397. doi: 10.1177/1352458518790397.
    PubMed     Text format     Abstract available


  59. PETERSEN ER, Sondergaard HB, Laursen JH, Olsson AG, et al
    Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis.
    Mult Scler. 2018 Aug 2:1352458518791753. doi: 10.1177/1352458518791753.
    PubMed     Text format     Abstract available


  60. DI STADIO A, Ralli M
    Inner ear involvement in multiple sclerosis: An underestimated condition?
    Mult Scler. 2018;24:1264-1265.
    PubMed     Text format    


  61. BHAN A, Jacobsen C, Myhr KM, Dalen I, et al
    Neurofilaments and 10-year follow-up in multiple sclerosis.
    Mult Scler. 2018 Aug 1:1352458518782005. doi: 10.1177/1352458518782005.
    PubMed     Text format     Abstract available


    July 2018
  62. YANG R, Dunn JF
    Multiple sclerosis disease progression: Contributions from a hypoxia-inflammation cycle.
    Mult Scler. 2018 Jul 27:1352458518791683. doi: 10.1177/1352458518791683.
    PubMed     Text format     Abstract available


  63. SACCA F, Lanzillo R, Signori A, Maniscalco GT, et al
    Determinants of therapy switch in multiple sclerosis treatment-naive patients: A real-life study.
    Mult Scler. 2018 Jul 25:1352458518790390. doi: 10.1177/1352458518790390.
    PubMed     Text format     Abstract available


  64. HYUN JW, Kim W, Huh SY, Park MS, et al
    Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome.
    Mult Scler. 2018 Jul 25:1352458518790702. doi: 10.1177/1352458518790702.
    PubMed     Text format     Abstract available


  65. HOLM HANSEN R, Hojsgaard Chow H, Sellebjerg F, Rode von Essen M, et al
    Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Jul 25:1352458518790417. doi: 10.1177/1352458518790417.
    PubMed     Text format     Abstract available


  66. COHEN JA, Comi G, Arnold DL, Bar-Or A, et al
    Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884.
    PubMed     Text format     Abstract available


  67. LIN F, Zivadinov R, Hagemeier J, Weinstock-Guttman B, et al
    Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition.
    Mult Scler. 2018 Jul 1:1352458518788218. doi: 10.1177/1352458518788218.
    PubMed     Text format     Abstract available


  68. SENDERS A, Hanes D, Bourdette D, Carson K, et al
    Impact of mindfulness-based stress reduction for people with multiple sclerosis at 8 weeks and 12 months: A randomized clinical trial.
    Mult Scler. 2018 Jul 1:1352458518786650. doi: 10.1177/1352458518786650.
    PubMed     Text format     Abstract available


  69. FISSOLO N, Cervera-Carles L, Villar Guimerans LM, Lleo A, et al
    Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis.
    Mult Scler. 2018 Jul 1:1352458518786055. doi: 10.1177/1352458518786055.
    PubMed     Text format     Abstract available


  70. OSHIMA Y, Tanimoto T, Yuji K, Tojo A, et al
    Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Mult Scler. 2018 Jul 1:1352458518786075. doi: 10.1177/1352458518786075.
    PubMed     Text format     Abstract available


  71. WIJNANDS JM, Zhu F, Kingwell E, Zhao Y, et al
    Five years before multiple sclerosis onset: Phenotyping the prodrome.
    Mult Scler. 2018 Jul 1:1352458518783662. doi: 10.1177/1352458518783662.
    PubMed     Text format     Abstract available


  72. WONG YYM, van der Vuurst de Vries RM, van Pelt ED, Ketelslegers IA, et al
    T-cell activation marker sCD27 is associated with clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes.
    Mult Scler. 2018 Jul 1:1352458518786655. doi: 10.1177/1352458518786655.
    PubMed     Text format     Abstract available


  73. KEARNEY H
    Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - No.
    Mult Scler. 2018 Jul 1:1352458518770279. doi: 10.1177/1352458518770279.
    PubMed     Text format    


  74. SASTRE-GARRIGA J
    Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Commentary.
    Mult Scler. 2018 Jul 1:1352458518783362. doi: 10.1177/1352458518783362.
    PubMed     Text format    


  75. CORTESE R, Ciccarelli O
    Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Yes.
    Mult Scler. 2018 Jul 1:1352458518778010. doi: 10.1177/1352458518778010.
    PubMed     Text format    


    June 2018
  76. MESCHERIAKOVA JY, Verkerk AJ, Amin N, Uitterlinden AG, et al
    Linkage analysis and whole exome sequencing identify a novel candidate gene in a Dutch multiple sclerosis family.
    Mult Scler. 2018 Jun 1:1352458518777202. doi: 10.1177/1352458518777202.
    PubMed     Text format     Abstract available


  77. PUTHENPARAMPIL M, Zito A, Pantano G, Federle L, et al
    Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset.
    Mult Scler. 2018 Jun 1:1352458518779951. doi: 10.1177/1352458518779951.
    PubMed     Text format     Abstract available


  78. AL HUSSONA M, Kearney H, Fisher A, Lynch J, et al
    New onset seizures as a sole clinical presentation of multiple sclerosis.
    Mult Scler. 2018 Jun 1:1352458518781994. doi: 10.1177/1352458518781994.
    PubMed     Text format     Abstract available


  79. REDDEL SW, Barnett MH, Riminton S, Dugal T, et al
    Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study.
    Mult Scler. 2018 Jun 1:1352458518783673. doi: 10.1177/1352458518783673.
    PubMed     Text format     Abstract available


  80. CHEN J, Taylor B, Palmer AJ, Kirk-Brown A, et al
    Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis.
    Mult Scler. 2018 Jun 1:1352458518781971. doi: 10.1177/1352458518781971.
    PubMed     Text format     Abstract available


  81. MANOUCHEHRINIA A, Zhu F, Piani-Meier D, Lange M, et al
    Predicting risk of secondary progression in multiple sclerosis: A nomogram.
    Mult Scler. 2018 Jun 1:1352458518783667. doi: 10.1177/1352458518783667.
    PubMed     Text format     Abstract available


  82. GALLAGHER LG, Ilango S, Wundes A, Stobbe GA, et al
    Lifetime exposure to ultraviolet radiation and the risk of multiple sclerosis in the US radiologic technologists cohort study.
    Mult Scler. 2018 Jun 1:1352458518783343. doi: 10.1177/1352458518783343.
    PubMed     Text format     Abstract available


  83. MAGALHAES S, Banwell B, Bar-Or A, Fortier I, et al
    A framework for measurement and harmonization of pediatric multiple sclerosis etiologic research studies: The Pediatric MS Tool-Kit.
    Mult Scler. 2018 Jun 1:1352458518783345. doi: 10.1177/1352458518783345.
    PubMed     Text format     Abstract available


  84. ALVES-LEON SV, Lima MDR, Nunes PCG, Chimelli LMC, et al
    Zika virus found in brain tissue of a multiple sclerosis patient undergoing an acute disseminated encephalomyelitis-like episode.
    Mult Scler. 2018 Jun 1:1352458518781992. doi: 10.1177/1352458518781992.
    PubMed     Text format     Abstract available


    May 2018
  85. FROEHLICH A, Schmidt S, Landsberg J, Bieber T, et al
    Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod.
    Mult Scler. 2018 May 1:1352458518774444. doi: 10.1177/1352458518774444.
    PubMed     Text format    


  86. NAUTA IM, Balk LJ, Sonder JM, Hulst HE, et al
    The clinical value of the patient-reported multiple sclerosis neuropsychological screening questionnaire.
    Mult Scler. 2018 May 1:1352458518777295. doi: 10.1177/1352458518777295.
    PubMed     Text format     Abstract available


  87. ROMME CHRISTENSEN J, Komori M, von Essen MR, Ratzer R, et al
    CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
    Mult Scler. 2018 May 1:1352458518774880. doi: 10.1177/1352458518774880.
    PubMed     Text format     Abstract available


  88. MILLS EA, Mao-Draayer Y
    Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.
    Mult Scler. 2018 May 1:1352458518775550. doi: 10.1177/1352458518775550.
    PubMed     Text format     Abstract available


  89. VAN DER VUURST DE VRIES RM, Wong YYM, Mescheriakova JY, van Pelt ED, et al
    High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
    Mult Scler. 2018 May 1:1352458518775303. doi: 10.1177/1352458518775303.
    PubMed     Text format     Abstract available


  90. SCHEE JP, Viswanathan S
    Pure spinal multiple sclerosis: A possible novel entity within the multiple sclerosis disease spectrum.
    Mult Scler. 2018 May 1:1352458518775912. doi: 10.1177/1352458518775912.
    PubMed     Text format     Abstract available


  91. BOESEN MS, Koch-Henriksen N, Thygesen LC, Eriksson F, et al
    Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study.
    Mult Scler. 2018 May 1:1352458518771871. doi: 10.1177/1352458518771871.
    PubMed     Text format     Abstract available


  92. BAKER G, Nair KPS, Baster K, Rosato R, et al
    Reliability and acceptability of the Multiple Sclerosis Quality of Life-29 questionnaire in an English-speaking cohort.
    Mult Scler. 2018 May 1:1352458518776583. doi: 10.1177/1352458518776583.
    PubMed     Text format     Abstract available


  93. BEESLEY R, Anderson V, Harding KE, Joseph F, et al
    Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosis.
    Mult Scler. 2018 May 1:1352458518778007. doi: 10.1177/1352458518778007.
    PubMed     Text format    


  94. HUGOS CL, Cameron MH, Chen Z, Chen Y, et al
    A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Long-term (12-month) follow-up at one site.
    Mult Scler. 2018 May 1:1352458518775920. doi: 10.1177/1352458518775920.
    PubMed     Text format     Abstract available


  95. TSAGKAS C, Magon S, Gaetano L, Pezold S, et al
    Preferential spinal cord volume loss in primary progressive multiple sclerosis.
    Mult Scler. 2018 May 1:1352458518775006. doi: 10.1177/1352458518775006.
    PubMed     Text format     Abstract available


  96. MARANZANO J, Till C, Assemlal HE, Fonov V, et al
    Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI.
    Mult Scler. 2018 May 1:1352458518779952. doi: 10.1177/1352458518779952.
    PubMed     Text format     Abstract available


  97. BJORNEVIK K, Myhr KM, Beiske A, Bjerve KS, et al
    alpha-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.
    Mult Scler. 2018 May 1:1352458518779925. doi: 10.1177/1352458518779925.
    PubMed     Text format     Abstract available


    April 2018
  98. ALMEIDA KJ, Barreto-Soares RV, Campos-Sousa RN, Campos-Sousa MG, et al
    Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518763091. doi: 10.1177/1352458518763091.
    PubMed     Text format     Abstract available


  99. MCNICHOLAS N, Lockhart A, Yap SM, O'Connell K, et al
    New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770088. doi: 10.1177/1352458518770088.
    PubMed     Text format     Abstract available


  100. KREMER D, Kury P, Hartung HP
    ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518768770. doi: 10.1177/1352458518768770.
    PubMed     Text format     Abstract available


  101. KOBELT G, Langdon D, Jonsson L
    The effect of self-assessed fatigue and subjective cognitive impairment on work capacity: The case of multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518769837. doi: 10.1177/1352458518769837.
    PubMed     Text format     Abstract available


  102. VAVASOUR IM, Tam R, Li DK, Laule C, et al
    A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.
    Mult Scler. 2018 Apr 1:1352458518770085. doi: 10.1177/1352458518770085.
    PubMed     Text format     Abstract available


  103. MARRIE RA, Montalban X
    Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night.
    Mult Scler. 2018;24:558-562.
    PubMed     Text format    


  104. LORSCHEIDER J, Benkert P, Lienert C, Hanni P, et al
    Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518768433. doi: 10.1177/1352458518768433.
    PubMed     Text format     Abstract available


  105. SAUL A, Taylor B, Simpson S Jr, Ponsonby AL, et al
    Polymorphism in the serotonin transporter gene polymorphisms ( 5-HTTLPR) modifies the association between significant life events and depression in people with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770021. doi: 10.1177/1352458518770021.
    PubMed     Text format     Abstract available


  106. LLUFRIU S, Rocca MA, Pagani E, Riccitelli GC, et al
    Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis.
    Mult Scler. 2018 Apr 1:1352458518771838. doi: 10.1177/1352458518771838.
    PubMed     Text format     Abstract available


  107. CREARY LE, Mallempati KC, Gangavarapu S, Caillier SJ, et al
    Deconstruction of HLA-DRB1*04:01:01 and HLA-DRB1*15:01:01 class II haplotypes using next-generation sequencing in European-Americans with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770019. doi: 10.1177/1352458518770019.
    PubMed     Text format     Abstract available


  108. MCCLURG D, Bugge C, Elders A, Irshad T, et al
    Factors affecting continuation of clean intermittent catheterisation in people with multiple sclerosis: Results of the COSMOS mixed-methods study.
    Mult Scler. 2018 Apr 1:1352458518768722. doi: 10.1177/1352458518768722.
    PubMed     Text format     Abstract available


  109. WAGLEY S, Bokori-Brown M, Morcrette H, Malaspina A, et al
    Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518767327. doi: 10.1177/1352458518767327.
    PubMed     Text format     Abstract available


  110. GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan KW, et al
    Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
    Mult Scler. 2018 Apr 1:1352458518771875. doi: 10.1177/1352458518771875.
    PubMed     Text format     Abstract available


  111. GIORDANA MT, Cavalla P, Uccelli A, Laroni A, et al
    Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation.
    Mult Scler. 2018 Apr 1:1352458518763095. doi: 10.1177/1352458518763095.
    PubMed     Text format     Abstract available


  112. GIACOMINI PS
    Rebound disease in multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518772913. doi: 10.1177/1352458518772913.
    PubMed     Text format    


  113. HARMEL P, Schlunk F, Harms L
    Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report.
    Mult Scler. 2018 Apr 1:1352458517741191. doi: 10.1177/1352458517741191.
    PubMed     Text format     Abstract available


    March 2018
  114. KOENIG KA, Rao SM, Lowe MJ, Lin J, et al
    The role of the thalamus and hippocampus in episodic memory performance in patients with multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518760716. doi: 10.1177/1352458518760716.
    PubMed     Text format     Abstract available


  115. GOBEL K, Ruck T, Meuth SG
    Cytokine signaling in multiple sclerosis: Lost in translation.
    Mult Scler. 2018 Mar 1:1352458518763094. doi: 10.1177/1352458518763094.
    PubMed     Text format     Abstract available


  116. LEE JY, De Jager PL
    What is the epigenome and is it involved in multiple sclerosis?
    Mult Scler. 2018;24:268-269.
    PubMed     Text format    


  117. SILLER N, Kuhle J, Muthuraman M, Barro C, et al
    Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765666. doi: 10.1177/1352458518765666.
    PubMed     Text format     Abstract available


  118. SOWA P, Harbo HF, White NS, Celius EG, et al
    Restriction spectrum imaging of white matter and its relation to neurological disability in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765671. doi: 10.1177/1352458518765671.
    PubMed     Text format     Abstract available


  119. CORTI L, Ayrignac X, Carra Dalliere C, Charif M, et al
    Late activity rebound in non-active multiple sclerosis: A rare event.
    Mult Scler. 2018 Mar 1:1352458518765670. doi: 10.1177/1352458518765670.
    PubMed     Text format    


  120. CASTELLI L, Prosperini L, Pozzilli C
    Balance worsening associated with nabiximols in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765649. doi: 10.1177/1352458518765649.
    PubMed     Text format     Abstract available


  121. GRAETZ C, Groger A, Luessi F, Salmen A, et al
    Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541.
    PubMed     Text format     Abstract available


  122. HUA LH, Fan TH, Conway D, Thompson N, et al
    Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.
    Mult Scler. 2018 Mar 1:1352458518765656. doi: 10.1177/1352458518765656.
    PubMed     Text format     Abstract available


  123. LANZILLO R, Moccia M, Criscuolo C, Cennamo G, et al
    Optical coherence tomography angiography detects retinal vascular alterations in different phases of multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518768060. doi: 10.1177/1352458518768060.
    PubMed     Text format    


  124. VAN GEEST Q, Boeschoten RE, Keijzer MJ, Steenwijk MD, et al
    Fronto-limbic disconnection in patients with multiple sclerosis and depression.
    Mult Scler. 2018 Mar 1:1352458518767051. doi: 10.1177/1352458518767051.
    PubMed     Text format     Abstract available


  125. TOLEDANO M, Weinshenker BG, Kaufmann TJ, Parisi JE, et al
    Demographics and clinical characteristics of episodic hypothermia in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518767045. doi: 10.1177/1352458518767045.
    PubMed     Text format     Abstract available


  126. LEIBOVITCH EC, Lin CM, Billioux BJ, Graves J, et al
    Prevalence of salivary human herpesviruses in pediatric multiple sclerosis cases and controls.
    Mult Scler. 2018 Mar 1:1352458518765654. doi: 10.1177/1352458518765654.
    PubMed     Text format     Abstract available


    February 2018
  127. JAEGER S, Paul F, Scheel M, Brandt A, et al
    Multiple sclerosis-related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex.
    Mult Scler. 2018 Feb 1:1352458518758911. doi: 10.1177/1352458518758911.
    PubMed     Text format     Abstract available


  128. DE STEFANO N, Giorgio A, Tintore M, Pia Amato M, et al
    Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations.
    Mult Scler. 2018;24:214-221.
    PubMed     Text format    


  129. ROOSTAEI T, Sadaghiani S, Mashhadi R, Falahatian M, et al
    Convergent effects of a functional C3 variant on brain atrophy, demyelination, and cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Feb 1:1352458518760715. doi: 10.1177/1352458518760715.
    PubMed     Text format     Abstract available


  130. CAVALERA C, Rovaris M, Mendozzi L, Pugnetti L, et al
    Online meditation training for people with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2018 Feb 1:1352458518761187. doi: 10.1177/1352458518761187.
    PubMed     Text format     Abstract available


  131. CAMARA-LEMARROY CR, Castillo J, Sastre-Garriga J, Tintore M, et al
    Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.
    Mult Scler. 2018 Feb 1:1352458518761185. doi: 10.1177/1352458518761185.
    PubMed     Text format     Abstract available


  132. PIEHL F, Hillert J
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes.
    Mult Scler. 2018 Feb 1:1352458518757930. doi: 10.1177/1352458518757930.
    PubMed     Text format    


  133. CREE BA
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary.
    Mult Scler. 2018 Feb 1:1352458518760717. doi: 10.1177/1352458518760717.
    PubMed     Text format    


  134. WALLIN MT
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No.
    Mult Scler. 2018 Feb 1:1352458518757931. doi: 10.1177/1352458518757931.
    PubMed     Text format    


    January 2018
  135. HILVEN K, Vandebergh M, Smets I, Mallants K, et al
    Genetic basis for relapse rate in multiple sclerosis: Association with LRP2 genetic variation.
    Mult Scler. 2018 Jan 1:1352458517749894. doi: 10.1177/1352458517749894.
    PubMed     Text format     Abstract available


  136. FEUCHT N, Maier M, Lepennetier G, Pettenkofer M, et al
    Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517750009. doi: 10.1177/1352458517750009.
    PubMed     Text format     Abstract available


  137. DI STADIO A, Ralli M
    Inner ear involvement in multiple sclerosis: An underestimated condition?
    Mult Scler. 2018 Jan 1:1352458518750010. doi: 10.1177/1352458518750010.
    PubMed     Text format    


  138. DAMOTTE V, Lizee A, Tremblay M, Agrawal A, et al
    Harnessing electronic medical records to advance research on multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517747407. doi: 10.1177/1352458517747407.
    PubMed     Text format     Abstract available


  139. DE STEFANO N, Giorgio A
    Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al.
    Mult Scler. 2018 Jan 1:1352458517748476. doi: 10.1177/1352458517748476.
    PubMed     Text format    


  140. SCHIFFMANN I, Scheiderbauer J, Riemann-Lorenz K, Heesen C, et al
    Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?
    Mult Scler. 2018 Jan 1:1352458517749895. doi: 10.1177/1352458517749895.
    PubMed     Text format    


  141. SEGAL BM, Cohen JA, Antel J
    Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2017: Environmental factors, genetics, and epigenetics in MS susceptibility and clinical course.
    Mult Scler. 2018;24:4-5.
    PubMed     Text format     Abstract available


  142. TREMLETT H, Waubant E
    Gut microbiome and pediatric multiple sclerosis.
    Mult Scler. 2018;24:64-68.
    PubMed     Text format     Abstract available


  143. CASTRO K, Casaccia P
    Epigenetic modifications in brain and immune cells of multiple sclerosis patients.
    Mult Scler. 2018;24:69-74.
    PubMed     Text format     Abstract available


  144. TANKOU SK, Regev K, Healy BC, Cox LM, et al
    Investigation of probiotics in multiple sclerosis.
    Mult Scler. 2018;24:58-63.
    PubMed     Text format     Abstract available


  145. VOSKUHL RR, Sawalha AH, Itoh Y
    Sex chromosome contributions to sex differences in multiple sclerosis susceptibility and progression.
    Mult Scler. 2018;24:22-31.
    PubMed     Text format     Abstract available


  146. HAASE S, Haghikia A, Gold R, Linker RA, et al
    Dietary fatty acids and susceptibility to multiple sclerosis.
    Mult Scler. 2018;24:12-16.
    PubMed     Text format     Abstract available


  147. HARROUD A, Richards JB
    Mendelian randomization in multiple sclerosis: A causal role for vitamin D and obesity?
    Mult Scler. 2018;24:80-85.
    PubMed     Text format     Abstract available


  148. DOLEI A
    The aliens inside us: HERV-W endogenous retroviruses and multiple sclerosis.
    Mult Scler. 2018;24:42-47.
    PubMed     Text format     Abstract available


  149. CANTO E, Oksenberg JR
    Multiple sclerosis genetics.
    Mult Scler. 2018;24:75-79.
    PubMed     Text format     Abstract available


  150. WAUBANT E
    Effect of puberty on multiple sclerosis risk and course.
    Mult Scler. 2018;24:32-35.
    PubMed     Text format     Abstract available


  151. HODEL J, Bapst B, Outteryck O, Verclytte S, et al
    Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
    Mult Scler. 2018 Jan 1:1352458517750765. doi: 10.1177/1352458517750765.
    PubMed     Text format     Abstract available


  152. BOVE R, Healy BC, Musallam A, Soltany P, et al
    Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients.
    Mult Scler. 2018 Jan 1:1352458517750768. doi: 10.1177/1352458517750768.
    PubMed     Text format     Abstract available


  153. RIMKUS CM, Schoonheim MM, Steenwijk MD, Vrenken H, et al
    Gray matter networks and cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517751650. doi: 10.1177/1352458517751650.
    PubMed     Text format     Abstract available


  154. COHEN JA, Hunter SF, Brown TR, Gudesblatt M, et al
    Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
    Mult Scler. 2018 Jan 1:1352458518754716. doi: 10.1177/1352458518754716.
    PubMed     Text format     Abstract available


  155. BARONCINI D, Zaffaroni M, Moiola L, Lorefice L, et al
    Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.
    Mult Scler. 2018 Jan 1:1352458518754364. doi: 10.1177/1352458518754364.
    PubMed     Text format     Abstract available


  156. FORD HL, Wicks CR, Stroud A, Tennant A, et al
    Psychological determinants of job retention in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458518754362. doi: 10.1177/1352458518754362.
    PubMed     Text format     Abstract available


  157. ROY S, Drake A, Fuchs T, Dwyer MG, et al
    Longitudinal personality change associated with cognitive decline in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517753720. doi: 10.1177/1352458517753720.
    PubMed     Text format     Abstract available


  158. HAUPTS MR, Spill-Askeridis P, Humpert M, Seidel D, et al
    Acute exacerbations after decades of non-active chronic multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458518754365. doi: 10.1177/1352458518754365.
    PubMed     Text format    


  159. DI IOIA M, Farina D, di Tommaso V, Travaglini D, et al
    Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517743093. doi: 10.1177/1352458517743093.
    PubMed     Text format     Abstract available


  160. MEUNIER B, Rico A, Seguier J, Boutiere C, et al
    Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
    Mult Scler. 2018 Jan 1:1352458517729766. doi: 10.1177/1352458517729766.
    PubMed     Text format     Abstract available


  161. MONTALBAN X, Gold R, Thompson AJ, Otero-Romero S, et al
    ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517751049. doi: 10.1177/1352458517751049.
    PubMed     Text format     Abstract available


  162. LAVERY AM, Collins BN, Waldman AT, Hart CN, et al
    The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk.
    Mult Scler. 2018 Jan 1:1352458518757089. doi: 10.1177/1352458518757089.
    PubMed     Text format     Abstract available


    December 2017
  163. KROTH J, Ciolac D, Fleischer V, Koirala N, et al
    Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517748474. doi: 10.1177/1352458517748474.
    PubMed     Text format     Abstract available


  164. HUGOS CL, Chen Z, Chen Y, Turner AP, et al
    A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Short- and medium-term benefits.
    Mult Scler. 2017 Dec 1:1352458517745723. doi: 10.1177/1352458517745723.
    PubMed     Text format     Abstract available


  165. CALLESEN J, Richter C, Kristensen C, Sunesen I, et al
    Test-retest agreement and reliability of the Six Spot Step Test in persons with multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517745725. doi: 10.1177/1352458517745725.
    PubMed     Text format     Abstract available


  166. PEETERS LM
    Fair data for next-generation management of multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517748475. doi: 10.1177/1352458517748475.
    PubMed     Text format     Abstract available


    November 2017
  167. GRAN-RUAZ S, Mani A, O'Quinn S
    An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517739976. doi: 10.1177/1352458517739976.
    PubMed     Text format     Abstract available


  168. MANCARDI G, Sormani MP, Muraro PA, Boffa G, et al
    Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517742532. doi: 10.1177/1352458517742532.
    PubMed     Text format     Abstract available


  169. PIETROBONI AM, Dell'Arti L, Caprioli M, Scarioni M, et al
    The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients.
    Mult Scler. 2017 Nov 1:1352458517740214. doi: 10.1177/1352458517740214.
    PubMed     Text format     Abstract available


  170. MALHOTRA S, Sorosina M, Rio J, Peroni S, et al
    NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.
    Mult Scler. 2017 Nov 1:1352458517739137. doi: 10.1177/1352458517739137.
    PubMed     Text format     Abstract available


  171. MALINOVA TS, Dijkstra CD, de Vries HE
    Serotonin: A mediator of the gut-brain axis in multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517739975. doi: 10.1177/1352458517739975.
    PubMed     Text format     Abstract available


  172. ABBOUD H, Hill E, Siddiqui J, Serra A, et al
    Neuromodulation in multiple sclerosis.
    Mult Scler. 2017;23:1663-1676.
    PubMed     Text format     Abstract available


  173. FEYS P, Moumdjian L, Van Halewyck F, Wens I, et al
    Effects of an individual 12-week community-located "start-to-run" program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517740211. doi: 10.1177/1352458517740211.
    PubMed     Text format     Abstract available


  174. LOREFICE L, Fenu G, Sardu C, Frau J, et al
    Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy.
    Mult Scler. 2017 Nov 1:1352458517739989. doi: 10.1177/1352458517739989.
    PubMed     Text format     Abstract available


  175. WINGES KM, Murchison CF, Bourdette DN, Spain RI, et al
    Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort.
    Mult Scler. 2017 Nov 1:1352458517739136. doi: 10.1177/1352458517739136.
    PubMed     Text format     Abstract available


  176. UHER T, Vaneckova M, Krasensky J, Sobisek L, et al
    Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517742739. doi: 10.1177/1352458517742739.
    PubMed     Text format     Abstract available


  177. KAVALIUNAS A, Danylaite Karrenbauer V, Gyllensten H, Manouchehrinia A, et al
    Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability.
    Mult Scler. 2017 Nov 1:1352458517740212. doi: 10.1177/1352458517740212.
    PubMed     Text format     Abstract available


  178. AGIUS MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, et al
    Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
    Mult Scler. 2017 Nov 1:1352458517740641. doi: 10.1177/1352458517740641.
    PubMed     Text format     Abstract available


  179. SPITERI S, Hassa T, Claros-Salinas D, Dettmers C, et al
    Neural correlates of effort-dependent and effort-independent cognitive fatigue components in patients with multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517743090. doi: 10.1177/1352458517743090.
    PubMed     Text format     Abstract available


  180. RICCITELLI GC, Pagani E, Rodegher M, Colombo B, et al
    Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517743091. doi: 10.1177/1352458517743091.
    PubMed     Text format     Abstract available


    October 2017
  181. MOSS-MORRIS R, Norton S
    Aerobic exercise, cognitive behavioural therapy and energy conservation management for multiple sclerosis (MS) fatigue: Are three trials better than one?
    Mult Scler. 2017;23:1436-1440.
    PubMed     Text format    


  182. ZETTERBERG H, Teunissen C
    Fluid biomarkers for disease activity in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736151. doi: 10.1177/1352458517736151.
    PubMed     Text format    


  183. BOESEN F, Norgaard M, Trenel P, Rasmussen PV, et al
    Longer term effectiveness of inpatient multidisciplinary rehabilitation on health-related quality of life in MS patients: a pragmatic randomized controlled trial - The Danish MS Hospitals Rehabilitation Study.
    Mult Scler. 2017 Oct 1:1352458517735188. doi: 10.1177/1352458517735188.
    PubMed     Text format     Abstract available


  184. GIANFRANCESCO MA, Stridh P, Shao X, Rhead B, et al
    Genetic risk factors for pediatric-onset multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517733551. doi: 10.1177/1352458517733551.
    PubMed     Text format     Abstract available


  185. VAN KEMPEN ZL, Rispens T, Killestein J
    Response to "Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".
    Mult Scler. 2017 Oct 1:1352458517734073. doi: 10.1177/1352458517734073.
    PubMed     Text format    


  186. FOX RJ, Chataway J
    Advancing trial design in progressive multiple sclerosis.
    Mult Scler. 2017;23:1573-1578.
    PubMed     Text format     Abstract available


  187. MILLER DH, Thompson AJ
    Advancing trial design in progressive multiple sclerosis.
    Mult Scler. 2017;23:1571-1572.
    PubMed     Text format    


  188. MOCCIA M, de Stefano N, Barkhof F
    Imaging outcome measures for progressive multiple sclerosis trials.
    Mult Scler. 2017;23:1614-1626.
    PubMed     Text format     Abstract available


  189. PICHLER A, Khalil M, Langkammer C, Pinter D, et al
    The impact of vascular risk factors on brain volume and lesion load in patients with early multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736149. doi: 10.1177/1352458517736149.
    PubMed     Text format     Abstract available


  190. GLAZER CH, Tottenborg SS, Giwercman A, Brauner EV, et al
    Male factor infertility and risk of multiple sclerosis: A register-based cohort study.
    Mult Scler. 2017 Oct 1:1352458517734069. doi: 10.1177/1352458517734069.
    PubMed     Text format     Abstract available


  191. TINELLI M, Kanavos P, Efthymiadou O, Visintin E, et al
    Using IMPrESS to guide policy change in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517737388. doi: 10.1177/1352458517737388.
    PubMed     Text format     Abstract available


  192. DONADIEU M, Le Fur Y, Maarouf A, Gherib S, et al
    Metabolic counterparts of sodium accumulation in multiple sclerosis: A whole brain 23Na-MRI and fast 1H-MRSI study.
    Mult Scler. 2017 Oct 1:1352458517736146. doi: 10.1177/1352458517736146.
    PubMed     Text format     Abstract available


  193. FLEMING J, Hernandez G, Hartman L, Maksimovic J, et al
    Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial.
    Mult Scler. 2017 Oct 1:1352458517736377. doi: 10.1177/1352458517736377.
    PubMed     Text format     Abstract available


  194. BSTEH G, Hegen H, Teuchner B, Amprosi M, et al
    Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517740216. doi: 10.1177/1352458517740216.
    PubMed     Text format     Abstract available


  195. LEAVITT VM, Blanchard AR, Guo CY, Gelernt E, et al
    Aspirin is an effective pretreatment for exercise in multiple sclerosis: A double-blind randomized controlled pilot trial.
    Mult Scler. 2017 Oct 1:1352458517739138. doi: 10.1177/1352458517739138.
    PubMed     Text format     Abstract available


  196. DEKKER I, Sombekke MH, Witte BI, Geurts JJ, et al
    Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736147. doi: 10.1177/1352458517736147.
    PubMed     Text format     Abstract available


    September 2017
  197. TOBYNE SM, Ochoa WB, Bireley JD, Smith VM, et al
    Cognitive impairment and the regional distribution of cerebellar lesions in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517730132. doi: 10.1177/1352458517730132.
    PubMed     Text format     Abstract available


  198. FAZIA T, Pastorino R, Foco L, Han L, et al
    Investigating multiple sclerosis genetic susceptibility on the founder population of east-central Sardinia via association and linkage analysis of immune-related loci.
    Mult Scler. 2017 Sep 1:1352458517732841. doi: 10.1177/1352458517732841.
    PubMed     Text format     Abstract available


  199. HUPPKE P, Huppke B, Ellenberger D, Rostasy K, et al
    Therapy of highly active pediatric multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517732843. doi: 10.1177/1352458517732843.
    PubMed     Text format     Abstract available


  200. LANZILLO R, Cennamo G, Criscuolo C, Carotenuto A, et al
    Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517729463. doi: 10.1177/1352458517729463.
    PubMed     Text format     Abstract available


  201. COMBER L, Quinn G, McGuigan C, Galvin R, et al
    Medication usage and falls in people with multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517731912. doi: 10.1177/1352458517731912.
    PubMed     Text format     Abstract available


  202. MEINL I, Havla J, Hohlfeld R, Kumpfel T, et al
    Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517731913. doi: 10.1177/1352458517731913.
    PubMed     Text format     Abstract available


  203. GIOVANNONI G, Wiendl H, Turner B, Umans K, et al
    Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.
    Mult Scler. 2017 Sep 1:1352458517729464. doi: 10.1177/1352458517729464.
    PubMed     Text format     Abstract available


  204. KAPPOS L, Arnold DL, Bar-Or A, Camm AJ, et al
    Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517728343. doi: 10.1177/1352458517728343.
    PubMed     Text format     Abstract available


  205. BISECCO A, Nardo FD, Docimo R, Caiazzo G, et al
    Fatigue in multiple sclerosis: The contribution of resting-state functional connectivity reorganization.
    Mult Scler. 2017 Sep 1:1352458517730932. doi: 10.1177/1352458517730932.
    PubMed     Text format     Abstract available


  206. CHARVET LE, Dobbs B, Shaw MT, Bikson M, et al
    Remotely supervised transcranial direct current stimulation for the treatment of fatigue in multiple sclerosis: Results from a randomized, sham-controlled trial.
    Mult Scler. 2017 Sep 1:1352458517732842. doi: 10.1177/1352458517732842.
    PubMed     Text format     Abstract available


    August 2017
  207. BRUNDIN L, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Sweden.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  208. BATTAGLIA M, Kobelt G, Ponzio M, Berg J, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  209. BERGER T, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  210. DUBOIS B, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  211. OREJA-GUEVARA C, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  212. CALABRESE P, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  213. UITDEHAAG B, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  214. FLACHENECKER P, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  215. KOBELT G, Eriksson J, Phillips G, Berg J, et al
    The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  216. PENTEK M, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  217. BOYKO A, Kobelt G, Berg J, Boyko O, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  218. RASMUSSEN PV, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Denmark.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  219. LEBRUN-FRENAY C, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for France.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  220. THOMPSON A, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  221. SELMAJ K, Kobelt G, Berg J, Orlewska E, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  222. SA MJ, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  223. HAVRDOVA E, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic.
    Mult Scler. 2017;23.
    PubMed     Text format     Abstract available


  224. VERMOHLEN V, Schiller P, Schickendantz S, Drache M, et al
    Hippotherapy for patients with multiple sclerosis: A multicenter randomized controlled trial (MS-HIPPO).
    Mult Scler. 2017 Aug 1:1352458517721354. doi: 10.1177/1352458517721354.
    PubMed     Text format     Abstract available


  225. RUHRMANN S, Ewing E, Piket E, Kular L, et al
    Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes.
    Mult Scler. 2017 Aug 1:1352458517721356. doi: 10.1177/1352458517721356.
    PubMed     Text format     Abstract available


  226. LAROCCA NG, Hudson LD, Rudick R, Amtmann D, et al
    The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
    Mult Scler. 2017 Aug 1:1352458517723718. doi: 10.1177/1352458517723718.
    PubMed     Text format     Abstract available


  227. VAVASOUR IM, Huijskens SC, Li DK, Traboulsee AL, et al
    Global loss of myelin water over 5 years in multiple sclerosis normal-appearing white matter.
    Mult Scler. 2017 Aug 1:1352458517723717. doi: 10.1177/1352458517723717.
    PubMed     Text format     Abstract available


  228. BERGAMASCHI R, Cortese A, Pichiecchio A, Berzolari FG, et al
    Air pollution is associated to the multiple sclerosis inflammatory activity as measured by brain MRI.
    Mult Scler. 2017 Aug 1:1352458517726866. doi: 10.1177/1352458517726866.
    PubMed     Text format     Abstract available


  229. SEHR T, Proschmann U, Thomas K, Ziemssen T, et al
    Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".
    Mult Scler. 2017 Aug 1:1352458517726384. doi: 10.1177/1352458517726384.
    PubMed     Text format    


  230. LOUAPRE C, Govindarajan ST, Gianni C, Madigan N, et al
    Heterogeneous pathological processes account for thalamic degeneration in multiple sclerosis: Insights from 7 T imaging.
    Mult Scler. 2017 Aug 1:1352458517726382. doi: 10.1177/1352458517726382.
    PubMed     Text format     Abstract available


  231. SELLEBJERG F, Bornsen L, Ammitzboll C, Nielsen JE, et al
    Defining active progressive multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517726592. doi: 10.1177/1352458517726592.
    PubMed     Text format     Abstract available


  232. ZIMMER P, Bloch W, Schenk A, Oberste M, et al
    High-intensity interval exercise improves cognitive performance and reduces matrix metalloproteinases-2 serum levels in persons with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2017 Aug 1:1352458517728342. doi: 10.1177/1352458517728342.
    PubMed     Text format     Abstract available


  233. LEURS CE, van Kempen ZL, Dekker I, Balk LJ, et al
    Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.
    Mult Scler. 2017 Aug 1:1352458517726381. doi: 10.1177/1352458517726381.
    PubMed     Text format     Abstract available


  234. SOLOMON AJ, Watts R, Ontaneda D, Absinta M, et al
    Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.
    Mult Scler. 2017 Aug 1:1352458517726383. doi: 10.1177/1352458517726383.
    PubMed     Text format     Abstract available


  235. AFOLABI D, Albor C, Zalewski L, Altmann DR, et al
    Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517726380. doi: 10.1177/1352458517726380.
    PubMed     Text format     Abstract available


  236. FAISSNER S, Mahjoub Y, Mishra M, Haupeltshofer S, et al
    Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?
    Mult Scler. 2017 Aug 1:1352458517728811. doi: 10.1177/1352458517728811.
    PubMed     Text format     Abstract available


  237. KALINCIK T, Jokubaitis V, Spelman T, Horakova D, et al
    Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517728812. doi: 10.1177/1352458517728812.
    PubMed     Text format     Abstract available


  238. BOVE R, Chitnis T, Cree BA, Tintore M, et al
    SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.
    Mult Scler. 2017 Aug 1:1352458517726657. doi: 10.1177/1352458517726657.
    PubMed     Text format     Abstract available


  239. GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan K, et al
    Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
    Mult Scler. 2017 Aug 1:1352458517727603. doi: 10.1177/1352458517727603.
    PubMed     Text format     Abstract available


    July 2017
  240. MIGLIORE S, Curcio G, Couyoumdjian A, Ghazaryan A, et al
    Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol.
    Mult Scler. 2017 Jul 1:1352458517719149. doi: 10.1177/1352458517719149.
    PubMed     Text format     Abstract available


  241. KJOLHEDE T, Siemonsen S, Wenzel D, Stellmann JP, et al
    Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?
    Mult Scler. 2017 Jul 1:1352458517722645. doi: 10.1177/1352458517722645.
    PubMed     Text format     Abstract available


  242. TANAKA M, Kinoshita M, Tanaka K
    Intermittent drug holidays in fingolimod therapy for multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517722647. doi: 10.1177/1352458517722647.
    PubMed     Text format    


  243. RODRIGUEZ-LEAL FA, Haase R, Thomas K, Eisele JC, et al
    Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
    Mult Scler. 2017 Jul 1:1352458517720043. doi: 10.1177/1352458517720043.
    PubMed     Text format     Abstract available


  244. STAMPANONI BASSI M, Leocani L, Comi G, Iezzi E, et al
    Can pharmacological manipulation of LTP favor the effects of motor rehabilitation in multiple sclerosis?
    Mult Scler. 2017 Jul 1:1352458517721358. doi: 10.1177/1352458517721358.
    PubMed     Text format     Abstract available


  245. ROLF L, Muris AH, Mathias A, Du Pasquier R, et al
    Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517722646. doi: 10.1177/1352458517722646.
    PubMed     Text format     Abstract available


  246. BALDASSARI LE, Salter AR, Longbrake EE, Cross AH, et al
    Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS.
    Mult Scler. 2017 Jul 1:1352458517721357. doi: 10.1177/1352458517721357.
    PubMed     Text format     Abstract available


  247. DUNN N, Juto A, Ryner M, Manouchehrinia A, et al
    Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
    Mult Scler. 2017 Jul 1:1352458517720044. doi: 10.1177/1352458517720044.
    PubMed     Text format     Abstract available


  248. CANCELLI A, Cottone C, Giordani A, Migliore S, et al
    Personalized, bilateral whole-body somatosensory cortex stimulation to relieve fatigue in multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517720528. doi: 10.1177/1352458517720528.
    PubMed     Text format     Abstract available


    June 2017
  249. CHOI IY, Lee P, Adany P, Hughes AJ, et al
    In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517711568. doi: 10.1177/1352458517711568.
    PubMed     Text format     Abstract available


  250. SATTARNEZHAD N, Farrow S, Kimbrough D, Glanz B, et al
    Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients.
    Mult Scler. 2017 Jun 1:1352458517713667. doi: 10.1177/1352458517713667.
    PubMed     Text format     Abstract available


  251. LEE H, Nakamura K, Narayanan S, Brown R, et al
    Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517715811. doi: 10.1177/1352458517715811.
    PubMed     Text format     Abstract available


  252. BOESEN MS, Magyari M, Koch-Henriksen N, Thygesen LC, et al
    Pediatric-onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during 1977-2015: A nationwide population-based incidence study.
    Mult Scler. 2017 Jun 1:1352458517713669. doi: 10.1177/1352458517713669.
    PubMed     Text format     Abstract available


  253. PAKPOOR J, Seminatore B, Graves JS, Schreiner T, et al
    Dietary factors and pediatric multiple sclerosis: A case-control study.
    Mult Scler. 2017 Jun 1:1352458517713343. doi: 10.1177/1352458517713343.
    PubMed     Text format     Abstract available


  254. SALMEN A
    Clinical commentary on "Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab".
    Mult Scler. 2017 Jun 1:1352458517717810. doi: 10.1177/1352458517717810.
    PubMed     Text format    


  255. MULERO P, Auger C, Parolin L, Fonseca E, et al
    Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.
    Mult Scler. 2017 Jun 1:1352458517711569. doi: 10.1177/1352458517711569.
    PubMed     Text format     Abstract available


  256. FOLEY RW, Tagg NT, Schindler MK, Fenton KM, et al
    Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517702533. doi: 10.1177/1352458517702533.
    PubMed     Text format     Abstract available


  257. DOBRYAKOVA E, Hulst HE, Spirou A, Chiaravalloti ND, et al
    Fronto-striatal network activation leads to less fatigue in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717087. doi: 10.1177/1352458517717087.
    PubMed     Text format     Abstract available


  258. RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
    Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517719152. doi: 10.1177/1352458517719152.
    PubMed     Text format    


  259. YAP SM, McNicholas N, Hutchinson M, McGuigan C, et al
    Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis - Not always self-limiting, fully reversible or predictable.
    Mult Scler. 2017 Jun 1:1352458517719151. doi: 10.1177/1352458517719151.
    PubMed     Text format    


  260. WEYGANDT M, Wakonig K, Behrens J, Meyer-Arndt L, et al
    Brain activity, regional gray matter loss, and decision-making in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717089. doi: 10.1177/1352458517717089.
    PubMed     Text format     Abstract available


  261. HIDALGO DE LA CRUZ M, d'Ambrosio A, Valsasina P, Pagani E, et al
    Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717807. doi: 10.1177/1352458517717807.
    PubMed     Text format     Abstract available


  262. RUANO L, Branco M, Portaccio E, Goretti B, et al
    Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study.
    Mult Scler. 2017 Jun 1:1352458517717341. doi: 10.1177/1352458517717341.
    PubMed     Text format     Abstract available


  263. BOZ C, Terzi M, Zengin Karahan S, Sen S, et al
    Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717806. doi: 10.1177/1352458517717806.
    PubMed     Text format     Abstract available


    May 2017
  264. VAN KEMPEN ZL, Leurs CE, Witte BI, de Vries A, et al
    The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.
    Mult Scler. 2017 May 1:1352458517708464. doi: 10.1177/1352458517708464.
    PubMed     Text format     Abstract available


  265. GOVEROVER Y, Chiaravalloti N, Genova H, DeLuca J, et al
    A randomized controlled trial to treat impaired learning and memory in multiple sclerosis: The self-GEN trial.
    Mult Scler. 2017 May 1:1352458517709955. doi: 10.1177/1352458517709955.
    PubMed     Text format     Abstract available


  266. BENEDICT RH, Cohan S, Lynch SG, Riester K, et al
    Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
    Mult Scler. 2017 May 1:1352458517707345. doi: 10.1177/1352458517707345.
    PubMed     Text format     Abstract available


  267. FREILICH J, Manouchehrinia A, Trusheim M, Baird LG, et al
    Characterization of annual disease progression of multiple sclerosis patients: A population-based study.
    Mult Scler. 2017 May 1:1352458517706252. doi: 10.1177/1352458517706252.
    PubMed     Text format     Abstract available


  268. ZEYDAN B, Lowe VJ, Schwarz CG, Przybelski SA, et al
    Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707346. doi: 10.1177/1352458517707346.
    PubMed     Text format     Abstract available


  269. SHINODA K, Matsushita T, Nakamura Y, Masaki K, et al
    HLA-DRB1*04:05 allele is associated with intracortical lesions on three-dimensional double inversion recovery images in Japanese patients with multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707067. doi: 10.1177/1352458517707067.
    PubMed     Text format     Abstract available


  270. SALTER A, Thomas NP, Tyry T, Cutter GR, et al
    A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.
    Mult Scler. 2017 May 1:1352458517711274. doi: 10.1177/1352458517711274.
    PubMed     Text format     Abstract available


  271. SUMOWSKI JF, Leavitt VM, Rocca MA, Inglese M, et al
    Mesial temporal lobe and subcortical grey matter volumes differentially predict memory across stages of multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517708873. doi: 10.1177/1352458517708873.
    PubMed     Text format     Abstract available


  272. CAWLEY N, Tur C, Prados F, Plantone D, et al
    Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517709954. doi: 10.1177/1352458517709954.
    PubMed     Text format     Abstract available


  273. BALK LJ, Coric D, Nij Bijvank JA, Killestein J, et al
    Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517708463. doi: 10.1177/1352458517708463.
    PubMed     Text format     Abstract available


  274. PRINEAS JW, Parratt JDE
    Multiple sclerosis: Serum anti-CNS autoantibodies.
    Mult Scler. 2017 May 1:1352458517706037. doi: 10.1177/1352458517706037.
    PubMed     Text format     Abstract available


  275. PALOTAI M, Mike A, Cavallari M, Strammer E, et al
    Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517711273. doi: 10.1177/1352458517711273.
    PubMed     Text format     Abstract available


  276. MARINO M, Frisullo G, Di Sante G, Samengo DM, et al
    Low reliability of anti-KIR4.183-120 peptide auto-antibodies in multiple sclerosis patients.
    Mult Scler. 2017 May 1:1352458517711275. doi: 10.1177/1352458517711275.
    PubMed     Text format     Abstract available


  277. REDONDO J, Sarkar P, Kemp K, Virgo PF, et al
    Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro.
    Mult Scler. 2017 May 1:1352458517711276. doi: 10.1177/1352458517711276.
    PubMed     Text format     Abstract available


  278. BIBERACHER V, Schmidt P, Selter RC, Pernpeinter V, et al
    Fatigue in multiple sclerosis: Associations with clinical, MRI and CSF parameters.
    Mult Scler. 2017 May 1:1352458517712078. doi: 10.1177/1352458517712078.
    PubMed     Text format     Abstract available


  279. SMOOT K, Spinelli KJ, Stuchiner T, Lucas L, et al
    Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
    Mult Scler. 2017 May 1:1352458517709956. doi: 10.1177/1352458517709956.
    PubMed     Text format     Abstract available


  280. TORTORELLA C, Direnzo V, Ruggieri M, Zoccolella S, et al
    Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517711774. doi: 10.1177/1352458517711774.
    PubMed     Text format     Abstract available


  281. VAN DER VUURST DE VRIES RM, van den Dorpel JJ, Mescheriakova JY, Runia TF, et al
    Fatigue after a first attack of suspected multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517709348. doi: 10.1177/1352458517709348.
    PubMed     Text format     Abstract available


  282. VAN DEN AKKER LE, Beckerman H, Collette EH, Twisk JW, et al
    Cognitive behavioral therapy positively affects fatigue in patients with multiple sclerosis: Results of a randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517709361. doi: 10.1177/1352458517709361.
    PubMed     Text format     Abstract available


  283. HEINE M, Verschuren O, Hoogervorst EL, van Munster E, et al
    Does aerobic training alleviate fatigue and improve societal participation in patients with multiple sclerosis? A randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517696596. doi: 10.1177/1352458517696596.
    PubMed     Text format     Abstract available


  284. BLIKMAN LJ, van Meeteren J, Twisk JW, de Laat FA, et al
    Effectiveness of energy conservation management on fatigue and participation in multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517702751. doi: 10.1177/1352458517702751.
    PubMed     Text format     Abstract available


  285. KAPPOS L, Butzkueven H, Wiendl H, Spelman T, et al
    Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
    Mult Scler. 2017 May 1:1352458517709619. doi: 10.1177/1352458517709619.
    PubMed     Text format     Abstract available


  286. SORMANI MP
    Why non-inferiority is more challenging than superiority?
    Mult Scler. 2017;23:790-791.
    PubMed     Text format     Abstract available


  287. HOEPNER R, Kolb EM, Dahlhaus S, Hellwig K, et al
    Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
    Mult Scler. 2017;23:830-835.
    PubMed     Text format     Abstract available


  288. NETRAVATHI M, Saini J, Mahadevan A, Hari-Krishna B, et al
    Is pruritus an indicator of aquaporin-positive neuromyelitis optica?
    Mult Scler. 2017;23:810-817.
    PubMed     Text format     Abstract available


  289. PITTERI M, Romualdi C, Magliozzi R, Monaco S, et al
    Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study.
    Mult Scler. 2017;23:848-854.
    PubMed     Text format     Abstract available


    April 2017
  290. AL-LOUZI O, Button J, Newsome SD, Calabresi PA, et al
    Retrograde trans-synaptic visual pathway degeneration in multiple sclerosis: A case series.
    Mult Scler. 2017 Apr 1:1352458516679035. doi: 10.1177/1352458516679035.
    PubMed     Text format     Abstract available


  291. SIGNORI A, Izquierdo G, Lugaresi A, Hupperts R, et al
    Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
    Mult Scler. 2017 Apr 1:1352458517703800. doi: 10.1177/1352458517703800.
    PubMed     Text format     Abstract available


  292. SOLARI A, Giordano A, Patti F, Grasso MG, et al
    Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517704078. doi: 10.1177/1352458517704078.
    PubMed     Text format     Abstract available


  293. COHEN JA, Imrey PB, Planchon SM, Bermel RA, et al
    Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517703802. doi: 10.1177/1352458517703802.
    PubMed     Text format     Abstract available


  294. GIOVANNONI G, Tomic D, Bright JR, Havrdova E, et al
    "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517703193. doi: 10.1177/1352458517703193.
    PubMed     Text format     Abstract available


  295. MORANDI E, Tarlinton RE, Tanasescu R, Gran B, et al
    Human endogenous retroviruses and multiple sclerosis: Causation, association, or after-effect?
    Mult Scler. 2017 Apr 1:1352458517704711. doi: 10.1177/1352458517704711.
    PubMed     Text format     Abstract available


  296. KLAUSER AM, Wiebenga OT, Eijlers AJ, Schoonheim MM, et al
    Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517702534. doi: 10.1177/1352458517702534.
    PubMed     Text format     Abstract available


  297. AMATO MP
    The diagnostic dilemma of multiple sclerosis presenting with isolated cognitive and behavioral disorders.
    Mult Scler. 2017 Apr 1:1352458517705002. doi: 10.1177/1352458517705002.
    PubMed     Text format     Abstract available


  298. ZAMBON AA, Cecchetti G, Caso F, Santangelo R, et al
    Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case.
    Mult Scler. 2017 Apr 1:1352458517702550. doi: 10.1177/1352458517702550.
    PubMed     Text format     Abstract available


  299. CIAMPI E, Uribe-San-Martin R, Godoy-Santin J, Cruz JP, et al
    Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.
    Mult Scler. 2017 Apr 1:1352458517702968. doi: 10.1177/1352458517702968.
    PubMed     Text format     Abstract available


  300. POP R, Kipfer S
    Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517702535. doi: 10.1177/1352458517702535.
    PubMed     Text format     Abstract available


  301. PAREES I
    Clinical commentary on "Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis" and "Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients".
    Mult Scler. 2017 Apr 1:1352458517702555. doi: 10.1177/1352458517702555.
    PubMed     Text format     Abstract available


  302. BODINI B, Branzoli F, Poirion E, Garcia-Lorenzo D, et al
    Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy.
    Mult Scler. 2017 Apr 1:1352458517698249. doi: 10.1177/1352458517698249.
    PubMed     Text format     Abstract available


  303. KOLBER P, Droby A, Roebroeck A, Goebel R, et al
    A "kissing lesion": In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458516683267. doi: 10.1177/1352458516683267.
    PubMed     Text format     Abstract available


  304. KILSDONK ID, Schoonheim M, Wattjes MP
    In-vivo imaging of meningeal inflammation in multiple sclerosis: Presence of evidence or evidence of presence?
    Mult Scler. 2017 Apr 1:1352458517704924. doi: 10.1177/1352458517704924.
    PubMed     Text format    


  305. TOUSSAINT-DUYSTER LC, Wong YYM, Van der Cammen-van Zijp MH, Van Pelt-Gravesteijn D, et al
    Fatigue and physical functioning in children with multiple sclerosis and acute disseminated encephalomyelitis.
    Mult Scler. 2017 Apr 1:1352458517706038. doi: 10.1177/1352458517706038.
    PubMed     Text format     Abstract available


  306. HAGENS MH, Killestein J, Yaqub MM, van Dongen GA, et al
    Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study.
    Mult Scler. 2017 Apr 1:1352458517704507. doi: 10.1177/1352458517704507.
    PubMed     Text format     Abstract available


  307. SORMANI MP
    Indirect comparisons of treatment effects: Network meta-analyses.
    Mult Scler. 2017;23:510-512.
    PubMed     Text format     Abstract available


  308. BOUDOT DE LA MOTTE M, Louapre C, Bertrand A, Reach P, et al
    Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
    Mult Scler. 2017;23:614-616.
    PubMed     Text format     Abstract available


  309. AIRAS L, Rissanen E, Rinne J
    Imaging of microglial activation in MS using PET: Research use and potential future clinical application.
    Mult Scler. 2017;23:496-504.
    PubMed     Text format     Abstract available


  310. HUM S, Lapierre Y, Scott SC, Duquette P, et al
    Trajectory of MS disease course for men and women over three eras.
    Mult Scler. 2017;23:534-545.
    PubMed     Text format     Abstract available


  311. D'SOUZA M, Yaldizli O, John R, Vogt DR, et al
    Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study.
    Mult Scler. 2017;23:597-603.
    PubMed     Text format     Abstract available


  312. VERMERSCH P, Hobart J, Dive-Pouletty C, Bozzi S, et al
    Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?
    Mult Scler. 2017;23:604-613.
    PubMed     Text format     Abstract available


  313. CIAMPI E, Pareto D, Sastre-Garriga J, Vidal-Jordana A, et al
    Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
    Mult Scler. 2017;23:556-566.
    PubMed     Text format     Abstract available


  314. BROWNLEE WJ, Altmann DR, Alves Da Mota P, Swanton JK, et al
    Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome.
    Mult Scler. 2017;23:665-674.
    PubMed     Text format     Abstract available


  315. SORMANI MP, Kappos L, Radue EW, Cohen J, et al
    Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.
    Mult Scler. 2017;23:656-664.
    PubMed     Text format     Abstract available


    March 2017
  316. FEINSTEIN A, Pavisian B
    Multiple sclerosis and suicide.
    Mult Scler. 2017 Mar 1:1352458517702553. doi: 10.1177/1352458517702553.
    PubMed     Text format     Abstract available


  317. ASGARI N, Jarius S, Laustrup H, Skejoe HP, et al
    Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study.
    Mult Scler. 2017 Mar 1:1352458517699791. doi: 10.1177/1352458517699791.
    PubMed     Text format     Abstract available


  318. CHARVET LE, Shaw M, Frontario A, Langdon D, et al
    Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing.
    Mult Scler. 2017 Mar 1:1352458517701588. doi: 10.1177/1352458517701588.
    PubMed     Text format     Abstract available


  319. HOUTCHENS MK, Zapata LB, Curtis KM, Whiteman MK, et al
    Contraception for women with multiple sclerosis: Guidance for healthcare providers.
    Mult Scler. 2017 Mar 1:1352458517701314. doi: 10.1177/1352458517701314.
    PubMed     Text format     Abstract available


  320. RUGGIERI S, Fanelli F, Castelli L, Petsas N, et al
    Lesion symptom map of cognitive-postural interference in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517701313. doi: 10.1177/1352458517701313.
    PubMed     Text format     Abstract available


  321. TOURBAH A, Sedel F
    Reply to the letter: Biotinidase deficiency masquerading as multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517702554. doi: 10.1177/1352458517702554.
    PubMed     Text format    


  322. WOLF B
    Biotinidase deficiency masquerading as multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517702551. doi: 10.1177/1352458517702551.
    PubMed     Text format    


  323. GYLLENSTEN H, Wiberg M, Alexanderson K, Friberg E, et al
    Comparing costs of illness of multiple sclerosis in three different years: A population-based study.
    Mult Scler. 2017 Mar 1:1352458517702549. doi: 10.1177/1352458517702549.
    PubMed     Text format     Abstract available


  324. INEICHEN BV, Schneider MP, Hlavica M, Hagenbuch N, et al
    High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517703801. doi: 10.1177/1352458517703801.
    PubMed     Text format     Abstract available


  325. SORMANI MP
    Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts.
    Mult Scler. 2017;23:378-381.
    PubMed     Text format     Abstract available


  326. HUH SY, Kim SH, Hyun JW, Jeong IH, et al
    Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders.
    Mult Scler. 2017;23:413-419.
    PubMed     Text format     Abstract available


  327. GRAVES JS, Chohan H, Cedars B, Arnow S, et al
    Sex differences and subclinical retinal injury in pediatric-onset MS.
    Mult Scler. 2017;23:447-455.
    PubMed     Text format     Abstract available


    February 2017
  328. BACCHETTA F, Mathias A, Schluep M, Du Pasquier R, et al
    Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
    Mult Scler. 2017;23:300-303.
    PubMed     Text format     Abstract available


  329. HAMID SH, Elsone L, Mutch K, Solomon T, et al
    The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates.
    Mult Scler. 2017;23:228-233.
    PubMed     Text format     Abstract available


  330. SORMANI MP, Bruzzi P
    Estimating a treatment effect: Choosing between relative and absolute measures.
    Mult Scler. 2017;23:197-200.
    PubMed     Text format     Abstract available


  331. SORMANI MP, Muraro PA, Saccardi R, Mancardi G, et al
    NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
    Mult Scler. 2017;23:201-204.
    PubMed     Text format     Abstract available


    January 2017
  332. AMATO MP, Derfuss T, Hemmer B, Liblau R, et al
    Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.
    Mult Scler. 2017 Jan 6:1352458516686847. doi: 10.1177/1352458516686847.
    PubMed     Text format     Abstract available


  333. DECARD BF, Thone J, Haghikia A, Bornke C, et al
    Listeria rhombencephalitis mimicking a demyelinating event in an immunocompetent young patient.
    Mult Scler. 2017;23:123-125.
    PubMed     Text format     Abstract available


  334. GIRARD B, Bonnemains C, Schmitt E, Raffo E, et al
    Biotinidase deficiency mimicking neuromyelitis optica beginning at the age of 4: A treatable disease.
    Mult Scler. 2017;23:119-122.
    PubMed     Text format     Abstract available


  335. LAROCHELLE C, Metz I, Lecuyer MA, Terouz S, et al
    Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal.
    Mult Scler. 2017;23:72-81.
    PubMed     Text format     Abstract available


  336. BURTON JM, Eliasziw M, Trufyn J, Tung C, et al
    A prospective cohort study of vitamin D in optic neuritis recovery.
    Mult Scler. 2017;23:82-93.
    PubMed     Text format     Abstract available


  337. HAAS J, Schneider K, Schwarz A, Korporal-Kuhnke M, et al
    Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
    Mult Scler. 2017;23:114-118.
    PubMed     Text format     Abstract available


  338. KALINCIK T, Sormani MP
    Reporting treatment outcomes in observational data: A fine balance.
    Mult Scler. 2017;23:21-22.
    PubMed     Text format     Abstract available


  339. SORMANI MP
    Subgroup analysis in MS trials.
    Mult Scler. 2017;23:34-35.
    PubMed     Text format     Abstract available


    October 2015
  340. WILLIS MD, Harding KE, Pickersgill TP, Wardle M, et al
    Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
    Mult Scler. 2015 Oct 29. pii: 1352458515614092.
    PubMed     Text format     Abstract available


  341. UDDIN MN, Lebel RM, Seres P, Blevins G, et al
    Spin echo transverse relaxation and atrophy in multiple sclerosis deep gray matter: A two-year longitudinal study.
    Mult Scler. 2015 Oct 26. pii: 1352458515614091.
    PubMed     Text format     Abstract available


  342. AHLBRECHT J, Martino F, Pul R, Skripuletz T, et al
    Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.
    Mult Scler. 2015 Oct 22. pii: 1352458515613641.
    PubMed     Text format     Abstract available


  343. ROCCA MA, Meani A, Riccitelli GC, Colombo B, et al
    Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue.
    Mult Scler. 2015 Oct 22. pii: 1352458515614407.
    PubMed     Text format     Abstract available


  344. HEITMANN H, Biberacher V, Tiemann L, Buck D, et al
    Prevalence of neuropathic pain in early multiple sclerosis.
    Mult Scler. 2015 Oct 19. pii: 1352458515613643.
    PubMed     Text format     Abstract available


  345. LANZILLO R, Quarantelli M, Pozzilli C, Trojano M, et al
    No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon beta1a therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
    Mult Scler. 2015 Oct 14. pii: 1352458515611222.
    PubMed     Text format     Abstract available


  346. KARAKY M, Alcina A, Fedetz M, Barrionuevo C, et al
    The multiple sclerosis-associated regulatory variant rs10877013 affects expression of CYP27B1 and VDR under inflammatory or vitamin D stimuli.
    Mult Scler. 2015 Oct 14. pii: 1352458515610208.
    PubMed     Text format     Abstract available


  347. SANDBERG L, Bistrom M, Salzer J, Vagberg M, et al
    Vitamin D and axonal injury in multiple sclerosis.
    Mult Scler. 2015 Oct 13. pii: 1352458515606986.
    PubMed     Text format     Abstract available


  348. ZECCA C, Disanto G, Sormani MP, Riccitelli GC, et al
    Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis.
    Mult Scler. 2015 Oct 12. pii: 1352458515599246.
    PubMed     Text format     Abstract available


  349. HEDSTROM AK, Olsson T, Alfredsson L
    Smoking is a major preventable risk factor for multiple sclerosis.
    Mult Scler. 2015 Oct 12. pii: 1352458515609794.
    PubMed     Text format     Abstract available


  350. LONGBRAKE EE, Ramsbottom MJ, Cantoni C, Ghezzi L, et al
    Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
    Mult Scler. 2015 Oct 12. pii: 1352458515608961.
    PubMed     Text format     Abstract available


  351. AKHTAR S, Alroughani R, Ahmed SF, Al-Hashel JY, et al
    Prognostic indicators of secondary progression in a paediatric-onset multiple sclerosis cohort in Kuwait.
    Mult Scler. 2015 Oct 9. pii: 1352458515608960.
    PubMed     Text format     Abstract available


  352. SIGNORIELLO E, Lanzillo R, Brescia Morra V, Di Iorio G, et al
    Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.
    Mult Scler. 2015 Oct 9. pii: 1352458515604381.
    PubMed     Text format     Abstract available


  353. EISELE P, Konstandin S, Griebe M, Szabo K, et al
    Heterogeneity of acute multiple sclerosis lesions on sodium (23Na) MRI.
    Mult Scler. 2015 Oct 9. pii: 1352458515609430.
    PubMed     Text format     Abstract available


  354. RICCELLI R, Passamonti L, Cerasa A, Nigro S, et al
    Individual differences in depression are associated with abnormal function of the limbic system in multiple sclerosis patients.
    Mult Scler. 2015 Oct 9. pii: 1352458515606987.
    PubMed     Text format     Abstract available


  355. DEGN M, Modvig S, Dyring-Andersen B, Bonefeld CM, et al
    Increased prevalence of lymphoid tissue inducer cells in the cerebrospinal fluid of patients with early multiple sclerosis.
    Mult Scler. 2015 Oct 9. pii: 1352458515609795.
    PubMed     Text format     Abstract available


  356. MACDONELL R, Nagels G, Laplaud DA, Pozzilli C, et al
    Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
    Mult Scler. 2015 Oct 7. pii: 1352458515606809.
    PubMed     Text format     Abstract available


  357. BOVE R, Healy BC, Musallam A, Glanz BI, et al
    Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort.
    Mult Scler. 2015 Oct 7. pii: 1352458515606211.
    PubMed     Text format     Abstract available


  358. VERCELLINO M, Fenoglio C, Galimberti D, Mattioda A, et al
    Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis.
    Mult Scler. 2015 Oct 7. pii: 1352458515610646.
    PubMed     Text format     Abstract available


  359. TILLEMA JM, Hulst HE, Rocca MA, Vrenken H, et al
    Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study.
    Mult Scler. 2015 Oct 2. pii: 1352458515607650.
    PubMed     Text format     Abstract available


  360. RATZER R, Iversen P, Bornsen L, Dyrby TB, et al
    Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.
    Mult Scler. 2015 Oct 2. pii: 1352458515605908.
    PubMed     Text format     Abstract available


  361. KEARNEY H, Miszkiel KA, Yiannakas MC, Altmann DR, et al
    Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis.
    Mult Scler. 2015 Oct 2. pii: 1352458515604905.
    PubMed     Text format     Abstract available


    September 2015
  362. GUTTMANN CR, Rousset M, Roch JA, Hannoun S, et al
    Multiple sclerosis lesion formation and early evolution revisited: A weekly high-resolution magnetic resonance imaging study.
    Mult Scler. 2015 Sep 11. pii: 1352458515600247.
    PubMed     Text format     Abstract available


  363. MARTINEZ-RODRIGUEZ JE, Cobo-Calvo A, Villar LM, Munteis E, et al
    Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis.
    Mult Scler. 2015 Sep 11. pii: 1352458515601215.
    PubMed     Text format     Abstract available


  364. UHER T, Horakova D, Tyblova M, Zeman D, et al
    Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.
    Mult Scler. 2015 Sep 11. pii: 1352458515601903.
    PubMed     Text format     Abstract available


  365. BINZER S, Stenager E, Binzer M, Kyvik KO, et al
    Genetic analysis of the isolated Faroe Islands reveals SORCS3 as a potential multiple sclerosis risk gene.
    Mult Scler. 2015 Sep 11. pii: 1352458515602338.
    PubMed     Text format     Abstract available


  366. SIMULA S, Laitinen T, Laitinen TM, Tarkiainen T, et al
    Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis.
    Mult Scler. 2015 Sep 11. pii: 1352458515604384.
    PubMed     Text format     Abstract available


    August 2015
  367. GONSETTE R, Debouverie M, Sindic C, Ferre JC, et al
    Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease.
    Mult Scler. 2015 Aug 18. pii: 1352458515601902.
    PubMed     Text format     Abstract available


  368. BHARGAVA P, Steele SU, Waubant E, Revirajan NR, et al
    Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls.
    Mult Scler. 2015 Aug 18. pii: 1352458515600248.
    PubMed     Text format     Abstract available


  369. TACCONI P, Peltz MT, Lorefice L, Marrosu MG, et al
    Facial synkinesis as a first symptom of multiple sclerosis.
    Mult Scler. 2015 Aug 5. pii: 1352458515584415.
    PubMed     Text format     Abstract available


  370. MILLER DM, Bethoux F, Victorson D, Nowinski CJ, et al
    Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis.
    Mult Scler. 2015 Aug 3. pii: 1352458515599450.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: